XML 38 R28.htm IDEA: XBRL DOCUMENT
v3.23.3

Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables) | 3 Months Ended
--- | ---
Sep. 30, 2023
Notes Tables |
Schedule of the Consolidated Changes in Equity | Consolidated Changes in Equity (amounts in thousands) ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Bio-Techne Shareholders |  | ​ | ​ |  |  | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Common Stock | ​ | Paid-in | ​ | Retained | ​ | Comprehensive | ​ | Noncontrolling | ​ | ​ | ​
​ | ​ | Shares | ​ | Amount | ​ | Capital | ​ | Earnings | ​ | Income(Loss) | ​ | Interest | ​ | Total
Balances at June 30, 2023 |  | 157,642 | ​ | $ | 1,576 | ​ | $ | 721,543 | ​ | $ | 1,309,461 | ​ | $ | (66,064) | ​ | $ | — | ​ | $ | 1,966,516
Net earnings |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | 50,993 | ​ |  | ​ | ​ |  | ​ | ​ |  | 50,993
Other comprehensive loss |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | (11,952) | ​ |  | ​ | ​ |  | (11,952)
Common stock issued for exercise of options |  | 633 | ​ |  | 6 | ​ |  | 12,877 | ​ |  | (15,460) | ​ |  | ​ | ​ |  | ​ | ​ |  | (2,577)
Common stock issued for restricted stock awards |  | 47 | ​ | ​ | 1 | ​ |  | 0 | ​ |  | (4,768) | ​ |  | ​ | ​ |  | ​ | ​ |  | (4,767)
Cash dividends |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | (12,654) | ​ |  | ​ | ​ |  | ​ | ​ |  | (12,654)
Stock-based compensation expense |  | ​ | ​ |  | ​ | ​ |  | 9,981 | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | 9,981
Common stock issued to employee stock purchase plan |  | 33 | ​ | ​ | 1 | ​ |  | 2,093 | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | 2,094
Employee stock purchase plan expense | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 112 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 112
Balances at September 30, 2023 |  | 158,355 | ​ | $ | 1,584 | ​ | $ | 746,606 | ​ | $ | 1,327,572 | ​ | $ | (78,016) | ​ | $ | — | ​ | $ | 1,997,746
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Bio-Techne Shareholders |  | ​ | ​ |  |  | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Common Stock | ​ | Paid-in | ​ | Retained | ​ | Comprehensive | ​ | Noncontrolling | ​ | ​ | ​
​ | ​ | Shares | ​ | Amount | ​ | Capital | ​ | Earnings | ​ | Income(Loss) | ​ | Interest | ​ | Total
Balances at June 30, 2022 |  | 156,644 | ​ | $ | 1,566 | ​ | $ | 652,467 | ​ | $ | 1,122,937 | ​ | $ | (75,200) | ​ | $ | (759) | ​ | $ | 1,701,011
Net earnings |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | 89,555 | ​ |  | ​ | ​ |  | 179 | ​ |  | 89,734
Other comprehensive loss |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | (16,762) | ​ |  | ​ | ​ |  | (16,762)
Reclassification of cumulative translation adjustment for Eminence to non-operating income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 152 | ​ | ​ | (33) | ​ | ​ | 119
Elimination of noncontrolling equity interest from sale of Eminence |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | 613 | ​ |  | 613
Share repurchases |  | (222) | ​ |  | (2) | ​ |  | ​ | ​ |  | (19,560) | ​ |  | ​ | ​ |  | ​ | ​ |  | (19,562)
Common stock issued for exercise of options |  | 425 | ​ |  | 5 | ​ |  | 9,418 | ​ |  | (11,428) | ​ |  | ​ | ​ |  | ​ | ​ |  | (2,005)
Common stock issued for restricted stock awards |  | 45 | ​ | ​ | 0 | ​ |  | 0 | ​ |  | (6,427) | ​ |  | ​ | ​ |  | ​ | ​ |  | (6,427)
Cash dividends |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | (12,545) | ​ |  | ​ | ​ |  | ​ | ​ |  | (12,545)
Stock-based compensation expense |  | ​ | ​ |  | ​ | ​ |  | 14,364 | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | 14,364
Common stock issued to employee stock purchase plan |  | 36 | ​ | ​ | 0 | ​ |  | 2,517 | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | 2,517
Employee stock purchase plan expense | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 97 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 97
Balances at September 30, 2022 |  | 156,928 | ​ | $ | 1,569 | ​ | $ | 678,863 | ​ | $ | 1,162,532 | ​ | $ | (91,810) | ​ | $ | — | ​ | $ | 1,751,154
Schedule of each component of other comprehensive income (loss) | The accumulated balances related to each component of other comprehensive income (loss) attributable to Bio-Techne are summarized as follows (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Unrealized | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Gains | ​ | Foreign | ​ | ​ | ​
​ | ​ | (Losses) on | ​ | Currency | ​ | ​ | ​
​ | ​ | Derivative | ​ | Translation | ​ | ​ | ​
​ |  | Instruments |  | Adjustments |  | Total
Balance as of June 30, 2023 | ​ | $ | 12,862 | ​ | $ | (78,926) | ​ | $ | (66,064)
Other comprehensive income (loss), before tax: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amounts before reclassifications, attributable to Bio-Techne | ​ | ​ | 1,587 | ​ | ​ | (11,069) | ​ | ​ | (9,482)
Amounts reclassified out | ​ | ​ | (2,539) | ​ | ​ | (698) | ​ | ​ | (3,237)
Total other comprehensive income (loss), before tax | ​ | ​ | (952) | ​ | ​ | (11,767) | ​ | ​ | (12,719)
Tax (expense)/benefit | ​ | ​ | (602) | ​ | ​ | (165) | ​ | ​ | (767)
Total other comprehensive income (loss), net of tax | ​ |  | (350) | ​ | ​ | (11,602) | ​ | ​ | (11,952)
Balance as of September 30, 2023(1) | ​ | $ | 12,512 | ​ | $ | (90,528) | ​ | $ | (78,016)
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Unrealized | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Gains | ​ | Foreign | ​ | ​ | ​
​ | ​ | (Losses) on | ​ | Currency | ​ | ​ | ​
​ | ​ | Derivative | ​ | Translation | ​ | ​ | ​
​ |  | Instruments |  | Adjustments |  | Total
Balance as of June 30, 2022 attributable to Bio-Techne | ​ | $ | 8,069 | ​ | $ | (83,269) | ​ | $ | (75,200)
Other comprehensive income (loss), before tax: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amounts before reclassifications, attributable to Bio-Techne | ​ | ​ | 4,376 | ​ | ​ | (21,457) | ​ | ​ | (17,081)
Amounts reclassified out | ​ | ​ | 417 | ​ | ​ | 152 | ​ | ​ | 569
Total other comprehensive income (loss), before tax | ​ | ​ | 4,793 | ​ | ​ | (21,305) | ​ | ​ | (16,512)
Tax (expense)/benefit | ​ | ​ | 98 | ​ | ​ | — | ​ | ​ | 98
Total other comprehensive income (loss), net of tax | ​ |  | 4,695 | ​ | ​ | (21,305) | ​ | ​ | (16,610)
Balance as of September 30, 2022(1) | ​ | $ | 12,764 | ​ | $ | (104,574) | ​ | $ | (91,810)
​ (1)The Company had a net deferred tax liability of $4,145 and $3,921 as of September 30, 2023 and September 30, 2022, respectively.

X
- Definition Tabular disclosure of the components of accumulated other comprehensive income (loss). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20 + Details
Name: | us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration